Marinus Pharmaceuticals Stock News

Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.

The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise

Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday! Stocks are up today as retail data came in better than expected

Marinus Pharmaceuticals (NASDAQ: MRNS ) stock is taking a beating on Monday after the pharmaceutical company announced results from a Phase 3 clinical trial. It's bad news for MRNS stockholders today

Start Time: 16:30 End Time: 17:36 March 1, 0000 ET Q4 2023 Earnings Conference Call March 05, 2024, 16:30 PM ET

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.76 per share a year ago.

Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Sonya Weigle - SVP, IR Scott Braunstein - CEO, President & Chairman Chris

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure d

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure d

Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system

Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in th

Marinus (NASDAQ:MRNS) Pharmaceuticals Inc shares climbed 20% to $7.02 on Tuesday after the pharmaceutical company dedicated to the development of therapeutics to treat seizure disorders revealed highl

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced

Marinus Pharmaceuticals (MRNS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stren